PMID- 36174995
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221012
IS  - 2092-7355 (Print)
IS  - 2092-7363 (Electronic)
IS  - 2092-7355 (Linking)
VI  - 14
IP  - 5
DP  - 2022 Sep
TI  - Bifidobacterium longum and Galactooligosaccharide Improve Skin Barrier 
      Dysfunction and Atopic Dermatitis-like Skin.
PG  - 549-564
LID - 10.4168/aair.2022.14.5.549 [doi]
AB  - PURPOSE: The beneficial effects of a combination therapy using Bifidobacterium 
      longum and galactooligosaccharide (GOS) for the treatment of atopic dermatitis 
      (AD) have not been elucidated. METHODS: Gene expressions of interleukin (IL)-4 
      and IL-13 from peripheral blood mononuclear cells and fecal abundance of B. 
      longum from 12-month-old infants were evaluated. Human primary epidermal 
      keratinocytes (HEKs) and hairless mice were treated with B. longum, GOS, B. 
      longum-derived extracellular vesicles (BLEVs), dinitrochlorobenzene (DNCB), or a 
      synbiotic mixture of B. longum and GOS. Expression of epidermal barrier proteins 
      and cytokines as well as serum immunoglobulin E (IgE) levels were analyzed in 
      HEKs and mice. Dermatitis scores, transepidermal water loss (TEWL), epidermal 
      thickness, and fecal B. longum abundance were evaluated in mice. RESULTS: Fecal 
      abundance of B. longum was negatively correlated with blood IL-13 expression in 
      infants. B. longum or BLEVs increased expression of filaggrin (FLG) and loricrin 
      (LOR) in HEKs. B. longum increased the efficacy of GOS to upregulate FLG and LOR 
      expressions in HEKs. Oral administration of GOS increased fecal abundance of B. 
      longum in mice. Oral administration of B. longum attenuated DNCB-induced skin 
      inflammation, abnormal TEWL, AD-like skin, and deficiency of epidermal barrier 
      proteins. Moreover, the combination of B. longum and GOS showed greater effects 
      to improve DNCB-induced skin inflammation, abnormal TEWL, AD-like skin, serum IgE 
      levels, IL-4 over-expression, and the deficiency of epidermal barrier proteins 
      than the administration of B. longum alone. CONCLUSIONS: B. longum and GOS 
      improve DNCB-induced skin barrier dysfunction and AD-like skin.
CI  - Copyright (c) 2022 The Korean Academy of Asthma, Allergy and Clinical Immunology * 
      The Korean Academy of Pediatric Allergy and Respiratory Disease.
FAU - Kim, Sukyung
AU  - Kim S
AUID- ORCID: 0000-0002-3204-1398
AD  - Department of Pediatrics, Hallym University Dongtan Sacred Heart Hospital, Hallym 
      University School of Medicine, Hwaseong, Korea.
FAU - Han, Song-Yi
AU  - Han SY
AUID- ORCID: 0000-0001-8274-5433
AD  - Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School 
      of Medicine, Seoul, Korea.
FAU - Lee, Jinyoung
AU  - Lee J
AUID- ORCID: 0000-0003-4571-2506
AD  - Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School 
      of Medicine, Seoul, Korea.
FAU - Kim, Na-Rae
AU  - Kim NR
AUID- ORCID: 0000-0002-9255-4144
AD  - Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School 
      of Medicine, Seoul, Korea.
FAU - Lee, Bo Ra
AU  - Lee BR
AUID- ORCID: 0000-0002-7718-1159
AD  - Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School 
      of Medicine, Seoul, Korea.
FAU - Kim, Hyunmi
AU  - Kim H
AUID- ORCID: 0000-0002-3323-9347
AD  - Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School 
      of Medicine, Seoul, Korea.
FAU - Kwon, Mijeoung
AU  - Kwon M
AUID- ORCID: 0000-0002-5740-7157
AD  - Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School 
      of Medicine, Seoul, Korea.
FAU - Ahn, Kangmo
AU  - Ahn K
AUID- ORCID: 0000-0001-7751-9829
AD  - Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School 
      of Medicine, Seoul, Korea.
FAU - Noh, Youngbae
AU  - Noh Y
AUID- ORCID: 0000-0002-1181-4099
AD  - Dairyteam, Lotte R&D Center, Seoul, Korea.
FAU - Kim, Sang Jong
AU  - Kim SJ
AUID- ORCID: 0000-0003-0281-3577
AD  - Dairyteam, Lotte R&D Center, Seoul, Korea.
FAU - Lee, Phyrim
AU  - Lee P
AUID- ORCID: 0000-0001-6700-2084
AD  - Dairyteam, Lotte R&D Center, Seoul, Korea.
FAU - Kim, Dongki
AU  - Kim D
AUID- ORCID: 0000-0001-5379-5853
AD  - Department of Translational Research and Cellular Therapeutics, Beckman Research 
      Institute of City of Hope, Duarte, CA, USA.
FAU - Kim, Byung Eui
AU  - Kim BE
AUID- ORCID: 0000-0003-4923-1814
AD  - Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School 
      of Medicine, Seoul, Korea.
AD  - Department of Pediatrics, National Jewish Health, Denver, CO, USA. 
      KimB@njhealth.org.
FAU - Kim, Jihyun
AU  - Kim J
AUID- ORCID: 0000-0001-8493-2881
AD  - Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School 
      of Medicine, Seoul, Korea. jhlovechild@gmail.com.
LA  - eng
GR  - 2017001360006/Ministry of Environment/Korea
PT  - Journal Article
PL  - Korea (South)
TA  - Allergy Asthma Immunol Res
JT  - Allergy, asthma & immunology research
JID - 101518382
PMC - PMC9523416
OTO - NOTNLM
OT  - Atopic dermatitis
OT  - Bifidobacterium longum
OT  - prebiotics
OT  - probiotics
OT  - synbiotics
COIS- Youngbae Noh, Sangjong Kim, and Phyrim Lee are employed by Lotte R&D Center. 
      The other authors declare that there are no potential conflicts of interests with 
      respect to the authorship and/or publication of this article.
EDAT- 2022/09/30 06:00
MHDA- 2022/09/30 06:01
PMCR- 2022/09/01
CRDT- 2022/09/29 20:12
PHST- 2022/04/06 00:00 [received]
PHST- 2022/06/30 00:00 [revised]
PHST- 2022/07/05 00:00 [accepted]
PHST- 2022/09/29 20:12 [entrez]
PHST- 2022/09/30 06:00 [pubmed]
PHST- 2022/09/30 06:01 [medline]
PHST- 2022/09/01 00:00 [pmc-release]
AID - 14.549 [pii]
AID - 10.4168/aair.2022.14.5.549 [doi]
PST - ppublish
SO  - Allergy Asthma Immunol Res. 2022 Sep;14(5):549-564. doi: 
      10.4168/aair.2022.14.5.549.